26 May 2020
Immunocore announces dosing of first patient with fourth ImmTAC
IMC-F106C studied for the treatment of advanced cancers that express PRAME
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 26 May 2020) Immunocore (or the “Company”), a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease, today announces the start of the first-in-human clinical trial of IMC-F106C, the fourth bispecific developed using the Company’s innovative ImmTAC® technology platform. Wholly owned IMC-F106C is focused on targeting tumours that express PRAME, a cancer-testis antigen (CTA) that is highly expressed in a broad range of solid and hematologic malignancies, and is being developed by Immunocore.
The trial (IMC-F106C-101) is designed to study the safety and preliminary activity of IMC-F106C as a monotherapy and in combination with a checkpoint inhibitor in patients with PRAME-expressing cancers.
“IMC-F106C is designed to re-direct T cells to attack PRAME expressing tumours. PRAME is an important target since it is broadly expressed in metastatic non-small cell lung cancer and other tumours of unmet need,” said David Berman, Head of Research and Development at Immunocore. “The start of this study is another significant milestone for Immunocore and we are pleased that clinical development has continued despite these unprecedented times as we aim to deliver medicines to transform patients’ lives.”